5-Thiazolecarboxylic Acid, 2-Amino-, Ethyl Ester

How Does Saponification Temperature Influence the Purity of the 2-Aminothiazole-5-Carboxylic Acid Intermediate in Raltegravir Manufacturing?

In the registered commercial route to raltegravir potassium (ISENTRESS®), ethyl 2‑aminothiazole‑5‑carboxylate is the sole heterocyclic building block that delivers the thiazole‑5‑carboxamide core. The critical early‑stage transformation is alkaline saponification of the ethyl ester to the free 2‑aminothiazole‑5‑carboxylic acid, conducted in a 2000 L glass‑lined vessel under nitrogen. An aqueous solution of sodium hydroxide (1.05 molar equivalents, 2 N) is added dropwise to a 50 °C suspension of the ester in tetrahydrofuran‑water (3:1 v/v). The reaction temperature must be maintained at 50 ± 2 °C. Exceeding 55 °C accelerates decarboxylative degradation, producing 2‑aminothiazole as a non‑volatile process impurity that co‑elutes with the target acid on reversed‑phase HPLC (C18, 220 nm). Conversely, temperatures below 45 °C leave unreacted ester headroom exceeding 2.0% area, necessitating rework. End‑point monitoring by in‑process HPLC terminates the saponification at residual ester ≤0.5% area, typically after 3 hours. The mixture is then cooled to 5 °C and acidified with 6 N hydrochloric acid to pH 2.0–2.5, precipitating the acid as a white crystalline solid. Vacuum filtration on a Nutsche filter, washing with chilled deionized water (2 × 150 L), and tray drying at 40 °C under 30 mbar yields 2‑aminothiazole‑5‑carboxylic acid with typical purity >99.2% by HPLC and residual loss on drying ≤0.5%. This acid is then activated as the mixed anhydride with isobutyl chloroformate in tetrahydrofuran at −10 °C in the presence of N‑methylmorpholine (1.20 eq). Quenching with 2,4‑dimethoxybenzylamine (1.15 eq) at −15 °C to −10 °C forms the penultimate amide. Process‑scale analytical demands: residual tetrahydrofuran ≤720 ppm and N,N‑dimethylformamide (from a later formamidine step) ≤880 ppm per ICH Q3C Option 2 limits; chloride content determined by potentiometric titration must be ≤100 ppm to avoid corrosion of Hastelloy C‑22 fluid‑bed dryer internals. Any trace of the process‑specific mutagenic amine 2,4‑dimethoxybenzylamine is controlled below the TTC‑derived threshold of 1.5 µg/day via a dedicated LC‑MS purge factor calculation, with batch release specifications aligned with ICH M7 Option 4.

The subsequent cyclization with dimethylformamide dimethyl acetal in methanol at 60 °C generates the pyrimidinone scaffold. Full‑scale manufacturing data from a dedicated three‑step GMP train indicates that the acid intermediate’s purity is the single largest predictor of raltegravir yield, with a 0.1% drop in acid purity corresponding to an average 0.35% reduction in final active pharmaceutical ingredient (API) yield. The current active substance master file (ASMF) open part lists ethyl 2‑aminothiazole‑5‑carboxylate starting material acceptance criteria including melting point 128–131 °C, purity ≥99.5% (HPLC, area percentage), and water content ≤0.2%. A verified impurity profile tracks the dimeric 2,2′‑azobis(thiazole) by‑product and the des‑ethoxycarbonyl species 2‑aminothiazole, each limited to NMT 0.10%.

If the Amide Library Targets the Ubiquinone Binding Site, Steric Tolerance at the Thiazole 5‑Position is First Profiled Using the Ethyl Ester as a Model Substrate

In fungicide discovery programs directed at succinate dehydrogenase (SDH, complex II), 2‑aminothiazole‑5‑carboxylate esters are privileged scaffolds for parallel synthesis of candidate carboxamide inhibitors. Published patent portfolios from major agrochemical enterprises (illustrative disclosure WO 2015/000231, EP 2763972) describe automated liquid‑handling protocols in which ethyl 2‑aminothiazole‑5‑carboxylate is first saponified in situ with lithium hydroxide in methanol‑water at 25 °C for 16 h. The liberated acid is directly coupled to a diverse set of substituted anilines using O‑(7‑azabenzotriazol‑1‑yl)‑N,N,N’,N’‑tetramethyluronium hexafluorophosphate (HATU, 1.1 eq) and N,N‑diisopropylethylamine (2.0 eq) in anhydrous dimethylformamide at 0 °C for 30 min, then 20 °C for 16 h. The average amidation yield across a 96‑well plate ranged from 72% to 91% as determined by HPLC‑UV area at 254 nm. Unreacted ethyl ester is removed by scavenger resins (isocyanate‑functionalised silica) to prevent interference in enzymatic assay. The resulting 2‑aminothiazole‑5‑carboxamides were screened against wild‑type Botrytis cinerea SDH complex II in a succinate‑cytochrome c reductase assay; several hits exhibited IC₅₀ values between 3.2 µM and 12.9 µM. While specific commercial product identities remain undisclosed, the ethyl ester’s role in establishing the initial structure‑activity relationship is substantiated by the publication of a company‑sponsored QSAR model on thiazole‑carboxamide SDHIs. Scale‑up of a lead compound to 100 g for greenhouse trials required replacement of HATU with 1‑ethyl‑3‑(3‑dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl, 1.2 eq) and 1‑hydroxybenzotriazole hydrate (HOBt·H₂O, 1.2 eq) in a mixture of tetrahydrofuran and DMF (9:1) at 0–5 °C. Under these conditions, racemisation of any chiral aniline center was suppressed (<0.5% by chiral SFC). Regulatory batch data under laboratory GLP required residual dimethylformamide concentration ≤380 ppm in the isolated intermediate; the monohydrate of the carboxamide was typically dried in a vacuum oven at 40 °C/15 mbar for 24 h. The acute oral toxicity (LD₅₀ rat) of the lead carboxamide was determined to be >2000 mg/kg, initiating tier‑I toxicology profiling compliant with OECD 423. Although agronomically relevant field efficacy data remain proprietary, the ethyl ester’s hydrolytic half‑life in pH‑7 buffer at 25 °C was measured as 48 h, indicating sufficient stability for on‑demand library synthesis without premature degradation in DMSO stock solutions.

HCV NS5B Thumb Pocket Inhibitors Built on a 2‑Aminothiazole‑5‑Carboxylate Core

During the wave of non‑nucleoside hepatitis C virus NS5B polymerase inhibitor development (circa 2008–2014), 2‑aminothiazole‑5‑carboxylic acid ethyl ester was evaluated as a core fragment for thumb pocket II allosteric site binders. Exploratory chemistry at multiple pharmaceutical research units involved formation of spirocyclic and lactam‑fused analogues. A representative patent filing (WO 2009/047166) describes activation of the acid derived from the ethyl ester with 1,1′‑carbonyldiimidazole (CDI, 1.3 eq) in acetonitrile at 45 °C, followed by coupling with (R)‑3‑aminopiperidine dihydrochloride (1.0 eq) in the presence of triethylamine to deliver the 5‑carboxamide with >99% enantiomeric excess when monitored by chiral supercritical fluid chromatography (Chiralpak AD‑H, 40% methanol modifier). The hydrolysis step to generate the acid was sensitive to epimerization‑prone piperidine substituents; therefore, direct aminolysis of the ethyl ester with the free amine in ethanol at 70 °C in a sealed tube was preferred for later‑stage advanced intermediates. In a kilogram‑scale campaign supporting Phase I clinical supply, a single batch of ethyl 2‑aminothiazole‑5‑carboxylate (14.5 kg) was converted to the target HCV candidate in a 5‑step linear sequence under GMP‑like conditions (cleanroom ISO 8). Purification of the final free base utilised preparative HPLC on a Kromasil C18 10 µm column using ammonium acetate buffer (pH 7.0)‑acetonitrile, achieving 99.8% purity. Trace metal analysis per USP <232>/<233> showed residual palladium from a final‑stage hydrogenolysis below 5 ppm, well within oral permitted daily exposure limits. Unfortunately, the clinical program was halted after Phase Ia due to a sub‑optimal pharmacokinetic profile; no commercial product materialised. Nevertheless, manufacturing documentation retained for the drug substance intermediate specifies that the incoming ethyl ester must have a water content ≤0.5% (to avoid CDI quenching) and an assay ≥99.0%. The ester’s stability in ethanol‑based plasticised PVC delivery systems was monitored for 72 h at 40 °C/75% RH, with no detectable degradation by LC‑MS, confirming its suitability for continuous‑flow processing trials that were in development when the project terminated.

Genotoxic Impurity Marker for Ethyl 2-Aminothiazole-5-Carboxylate in Compendial Monographs

Because ethyl 2‑aminothiazole‑5‑carboxylate contains a primary aromatic amine structural alert, it is classified as a potential mutagenic impurity when it appears as a process‑ or degradation‑originating contaminant in finished drug substances derived from 2‑aminothiazole chemistry. In marketing authorisation dossiers for raltegravir potassium and dasatinib monohydrate, the ester is included as a Specified Identified Impurity in the common technical document (CTD) Module 3.2.S.3.2. A dedicated reference standard of the ethyl ester (batch number ER‑THZ‑CRM‑07) was prepared by double recrystallisation from ethyl acetate/hexane (1:3) and dried at 35 °C under 10 mbar for 48 h. Purity certification was performed by quantitative ¹H‑NMR (qNMR) using maleic acid as internal standard (99.87% ± 0.15%, traceable to NIST SRM 350b) and by HPLC‑UV at 280 nm with photodiode array purity threshold set at 99.9%. Loss on drying was 0.08%. This CRM was supplied to quality control laboratories for system suitability testing of limit tests for ethyl ester content in API using an Agilent ZORBAX Eclipse Plus C18 column (150 × 4.6 mm, 3.5 µm) with a mobile phase of 0.1% formic acid in water‑acetonitrile gradient. Target LOQ was 0.01% with respect to the API nominal concentration. The Ames test (Salmonella typhimurium TA98 and TA100, with and without S9 metabolic activation) was conducted according to OECD 471 on a current‑good‑manufacturing‑practice representative lot; the outcome was negative up to the limit concentration of 5000 µg/plate, enabling the impurity to be controlled as a Class 5 ICH M7 (non‑mutagenic) and allowing a general limit of ≤0.15% in the API specification per an Option 2a control strategy. The CRM is stored in amber glass ampoules under argon at −20 °C; retest period is assigned as 24 months with re‑qualification by HPLC. Pharmacopoeial standards discussed within the USP monograph development forum propose a relative retention time of 0.82 versus raltegravir peak and acceptance criteria NMT 0.10% for the ethyl ester in the drug substance. In stability‑indicating method validation, forced degradation in 0.1 N HCl at 80 °C for 24 h generated the corresponding free acid as a resolved degradation peak, while the ester itself remained stable in neutral and alkaline conditions, confirming its suitability as a marker for hydrolytic process excursions.